-
公开(公告)号：US20210220377A1
公开(公告)日：2021-07-22
申请号：US17070271
申请日：2020-10-14
发明人： Wu ZHONG , Ruiyuan Cao , Gengfu Xiao , Zhihong Hu , Manli Wang , Leike Zhang , Wei Li , Yuexiang Li , Lei Zhao , Shiyong Fan , Song Li
IPC分类号： A61K31/685 , A61P31/14
摘要： The present application relates to use of a substituted aminopropionate compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof, and a pharmaceutical composition comprising the compound for the treatment of a disease or an infection caused by a SARS-CoV-2.
-
公开(公告)号：US20230119764A1
公开(公告)日：2023-04-20
申请号：US17908617
申请日：2020-07-13
发明人： Wu Zhong , Chengfeng Qin , Xinbo Zhou , Yongqiang Deng , Jiqiang Hu , Qingping Jin , Bin Yu , Ruiyuan Cao , Manli Wang , Xiaofeng Li , Nana Zhang , Shiyong Fan , Zhihong Hu , Song Li
IPC分类号： A61K31/4748 , A61P31/14
摘要： A compound represented by the general Formula I, a geometric isomer thereof, or a pharmaceutically acceptable salt thereof, and/or a solvate thereof, and/or a hydrate thereof for preventing and/or treating a pulmonary disease or symptom associated with SARS-CoV-2 or an asymptomatic or symptomatic SARS-CoV-2 infection, and an application of the compound represented by the general Formula I, the geometric isomer thereof, or the pharmaceutically acceptable salt thereof, and/or the solvate thereof, and/or the hydrate thereof in preparation of a product for preventing and/or treating a pulmonary disease or symptom associated with SARS-CoV-2 or asymptomatic or symptomatic SARS-CoV-2 infection,
-
公开(公告)号：US11318135B2
公开(公告)日：2022-05-03
申请号：US17378361
申请日：2021-07-16
发明人： Wu Zhong , Ruiyuan Cao , Cheng Cao , Ting Gao , Gengfu Xiao , Zhihong Hu , Manli Wang , Leike Zhang , Song Li
IPC分类号： A61K31/4965 , A61P31/14
摘要： The present application relates to a Favipiravir compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof, and a pharmaceutical composition comprising the compound for treating a coronavirus infection.
-
公开(公告)号：US20230077704A1
公开(公告)日：2023-03-16
申请号：US17794145
申请日：2020-07-15
发明人： Wu Zhong , Gengfu Xiao , Zhihong Hu , Manli Wang , Ruiyan Cao , Leike Zhang , Wei Li , Yuexiang Li , Lei Zhao , Song Li
IPC分类号： A61K31/426 , A61P31/14
摘要： Nitazoxanide represented by formula I and an active form thereof, tizoxanide compound, represented by formula II, a geometric isomer thereof and pharmaceutically acceptable salt thereof and/or solvate thereof and/or hydrate thereof, and a pharmaceutical composition containing this compound, used for preventing and/or treating coronavirus (such as SARS-CoV-2) infection.
-
公开(公告)号：US20230293485A1
公开(公告)日：2023-09-21
申请号：US18017471
申请日：2021-07-22
发明人： Ruiyuan Cao , Manli Wang , Wei Li , Lei Zhao , Jingjing Yang , Yuexiang Li , Shiyong Fan , Xinbo Zhou , Dian Xiao , Zhihong Hu , Song Li , Wu Zhong
IPC分类号： A61K31/366 , A61P31/14 , A61K31/365 , A61K31/357
CPC分类号： A61K31/366 , A61P31/14 , A61K31/365 , A61K31/357
摘要： The present invention relates to an application of an artemisinin compound in treatment of coronavirus infection. Specifically, the present invention provides an application of the compound, and a stereoisomer, a pharmaceutically acceptable salt, a solvate or a hydrate thereof in preparation of medicines. The medicines are used for treating diseases or infection caused by coronavirus (preferably SARS-CoV-2), and the compound is selected from one or more of artemisinin, arteether, artemether, artemisia ketone, dihydroartemisinin, artesunate, arteannuin B, and artemisinic acid.
-
公开(公告)号：US20230263811A1
公开(公告)日：2023-08-24
申请号：US18017710
申请日：2021-07-19
发明人： Wu Zhong , Yong Qin , Manli Wang , Ruiyuan Cao , Shiyong Fan , Zhihong Hu , Song Li
CPC分类号： A61K31/658 , A61K45/06 , A61P31/14
摘要： The present application relates to use of cannabidiol in the preparation of a drug for treating coronavirus infections. The present invention specifically relates to cannabidiol, or a geometric isomer, pharmaceutically acceptable salt, solvate or hydrate thereof, or use of a pharmaceutical composition comprising any one or more of the above components in the preparation of a drug for preventing and/or treating diseases or infections caused by a coronavirus.
-
公开(公告)号：US20230218606A1
公开(公告)日：2023-07-13
申请号：US17795471
申请日：2020-06-02
发明人： Wu Zhong , Gengfu Xiao , Zhihong Hu , Manli Wang , Leike Zhang , Ruiyuan Cao , Wei Li , Shiyong Fan , Xinbo Zhou , Song Li
IPC分类号： A61K31/4706 , A61P31/14
CPC分类号： A61K31/4706 , A61P31/14
摘要： Disclosed are hydroxychloroquine or chloroquine, or a geometric isomer thereof, or a pharmaceutically acceptable salt thereof, and/or a solvate thereof, and/or a hydrate thereof, and a pharmaceutical composition containing the above-mentioned compound, and the use thereof in the treatment of diseases or infections caused by SARS-CoV-2.
-
公开(公告)号：US20230071014A1
公开(公告)日：2023-03-09
申请号：US17797048
申请日：2020-07-15
发明人： Wu Zhong , Zhihong Hu , Gengfu Xiao , Ruiyuan Cao , Manli Wang , Leike Zhang , Wei Li , Shiyong Fan , Song Li
IPC分类号： A61K31/427 , A61P31/14
摘要： A use of ritonavir, or a geometric isomer, pharmaceutically acceptable salt, solvate, and/or hydrate thereof, and a pharmaceutical composition containing the above compound in treating a SARS-CoV-2 infections.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.015 秒)
